Investor Relations

IceCure is transforming healthcare by bringing the choice of advanced minimally invasive cryoablation treatment options for benign and malignant tumors to women's health and interventional oncology.

Latest News

IceCure Medical Reports Full Year 2023 Financial Results: Global ProSense® and Disposables Sales Increase 26% as Company Continues Transition to Commercial Phase and Expects to Submit ICE3 Breast Cancer Study Data to FDA this Month for Marketing Clearance

View Press Release

IceCure Submits FDA Regulatory Filing for New XSense™ Cryoablation System with Cryoprobes

View Press Release

IceCure Medical to Report 2023 Full Year Financial & Operational Results on April 3, 2024

View Press Release
Company Presentation

Latest Presentation

Company Presentation

February 2024 Fact sheet

Fact Sheet

February 2024 Fact sheet

Latest Event

Q4 2023 Results Conference Call

Company Overview

IceCure is transforming healthcare by bringing the choice of advanced minimally invasive cryoablation treatment options for benign and malignant tumors to women's health and interventional oncology. Its liquid-nitrogen based systems use ultra cold temperatures to destroy tumors by freezing them. Supported by clinical experience across multiple areas of cancer care, IceCure is opening the door for quick, convenient office-based and CT room procedures. Cryoablation - It's your choice.

Latest Financial Results

FY 2023

Fiscal Year Ended Dec 31, 2023

Latest Annual Filing

For Fiscal Year Ending Dec 31, 2023

Stock Snapshot

IR Contacts

Headquarters

IceCure Medical Ltd.
7 Ha’Eshel Street
PO Box 3163
Caesarea 3079504
Israel
T: +972-4-623-0333
F: +972-4-623-0222
investors@icecure-medical.com

Investor Relations

EVC Group
Michael Polyviou
Todd Kehrli
T: +1-732-933-2755
investors@icecure-medical.com
https://www.evcgroup.com

Transfer Agent

VStock Transfer, LLC
18 Lafayette Place
Woodmere, NY 11598
T: 212-828-8436
F: 646-536-3179
info@vstocktransfer.com